

New-to-Market Medical Pharmacy Products Currently Under Clinical Review by Medica

Updated 4/1/2024

Brand name	Generic name	J code	National Drug Codes (NDCs)	Date of FDA approval
Amtagvi	lifileucel	J9999	73776-0001-12	February 16, 2024
Aphexda	motixafortide	J3490	82737-0073-01	September 24, 2023
Lenmeldy	atidarsagene autotemcel	J3590	83222-0200-01	March 18, 2024
Tevimbra	tislelizumab	J9999	72579-0121-01	March 13, 2024
Winrevair	sotatercept-csrk	J3590	Multiple	March 26, 2024

Note: Drugs recently removed from this list have been addressed under new [Medica drug management policies](#).

This list is provided for our provider network's convenience and information. While this list is intended to be comprehensive, the U.S. Food and Drug Administration (FDA) approval process and its timing are outside of Medica's control. Medica reserves the right to adjust claims for any new-to-market medical pharmacy products as discussed in [the New-to-Market Medical Pharmacy Products coverage policy](#).